Medexus Pharmaceuticals (TSE:MDP - Free Report) had its target price lifted by Ventum Financial from C$5.00 to C$6.25 in a report issued on Thursday,BayStreet.CA reports. The brokerage currently has a buy rating on the stock.
A number of other equities research analysts also recently issued reports on MDP. Ventum Cap Mkts raised Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 17th. Leede Financial upgraded Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, January 22nd. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a report on Monday, December 23rd. Stifel Nicolaus lifted their price target on shares of Medexus Pharmaceuticals from C$4.50 to C$6.00 in a research report on Thursday. Finally, Raymond James raised shares of Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 price objective for the company in a research report on Wednesday, January 8th. Two investment analysts have rated the stock with a buy rating and five have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Strong Buy" and a consensus price target of C$6.13.
Check Out Our Latest Report on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Down 1.6 %
Shares of TSE MDP traded down C$0.06 during trading on Thursday, hitting C$3.79. 57,940 shares of the company traded hands, compared to its average volume of 189,994. The firm has a market capitalization of C$92.97 million, a P/E ratio of 75.80 and a beta of 1.96. The company has a 50-day moving average price of C$3.44 and a 200-day moving average price of C$2.78. Medexus Pharmaceuticals has a 1 year low of C$1.47 and a 1 year high of C$5.56.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Featured Stories
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
